All In Biotech

Drug Trial Radar · NCT07181187

Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

156

Actual

Start

Mar 26, 2024

Primary completion

Sep 24, 2025

Study completion May 7, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, vehicle-controlled phase II study of MH004 Ointment with a 28-week open-label long-term safety extension period. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and primary efficacy of MH004 Ointment in adolescents and adults with vitiligo.

Conditions

  • Vitiligo

Interventions

  • MH004 OintmentDrug

    MH004 1% ointment applied topically to the affected area as a thin film once or twice daily.

  • Vehicle OintmentDrug

    Matching vehicle ointment applied topically to the affected area as a thin film once or twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving Facial Vitiligo Area Scoring Index 50(F-VASI50) at Week 24.Time frame: Baseline; Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hangzhou Third People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.